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Introduction
Several forms of inflammatory arthritis are triggered by
infection with bacteria, including reactive arthritis (ReA)
following certain gastrointestinal or urogenital infections
[1], Lyme disease [2] and the arthritis associated with
streptococcal or neisseria infection. Each of these differs
from classical septic arthritis in that bacteria cannot readily
be isolated from the affected joints, although occasionally
Borrelia burgdorferi has been cultured from the synovial
fluid (SF) of some patients with Lyme arthritis [2,3], and
gonococci or meningococci can be cultured from joints in
the early phase of disease [4]. Because the joint is usually
sterile, these forms of arthritis have been considered to be
the result of some form of autoimmune reaction that was
triggered by an infection at a site distant from the joint.
However, in more recent studies bacterial antigens [5–7]
and, in several cases, bacterial DNA and/or RNA have
been identified in synovium or SF from selected patients
with ReA [8–10] and Lyme arthritis [11]. This implies that
organisms associated with these forms of arthritis do
reach the joint, although they may be present there in an
uncultivable state, and raises the possibility that joint
inflammation is driven by immune responses to bacterial
antigens without the need to evoke autoimmune mecha-
nisms. In Lyme disease both mechanisms have been sug-
gested for different phases of disease [12,13]: arthritis
driven by bacterial antigens in early disease that is
responsive to antibiotic treatment; and autoimmunity in
antibiotic-resistant, chronic disease caused by cross-
reactive T cells that are responsive to Borrelia OspA
bp = base pairs; RA = rheumatoid arthritis; ReA = reactive arthritis; RT = reverse transcription; SAPHO = synovitis, acne, pustulosis, hyperostosis,
osteitis; SF = synovial fluid.
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Abstract
In reactive and postinfectious arthritis the joints are generally
sterile but the presence of bacterial antigens and nucleic acids
has been reported. To investigate whether organisms traffic to
affected joints in these conditions, we performed reverse
transcription PCR using universal primers to amplify any
bacterial 16S rRNA sequences present in synovial fluid.
Bacterial sequences were detected in most cases, even after
treatment of the synovial fluid with DNase, implying the
presence of bacterial RNA and therefore of transcriptionally
active bacteria. Analysis of a large number of sequences
revealed that, as reported in rheumatoid arthritis, most were
derived from gut and skin commensals. Organisms known to
have triggered arthritis in each case were not found by
sequencing the products obtained using universal primers, but
could in some cases be shown to be present by amplifying with
species specific primers. This was the case for Yersinia
pseudotuberculosis and Chlamydia trachomatis. However, in
arthritis thought to be related to Campylobacter infection the
sequences obtained were not from Campylobacter jejuni or
C. coli, but from other Campylobacter spp. that are not known
to be associated with reactive arthritis and are probably
present as commensals in the gut. We conclude that although
rRNA from reactive arthritis associated organisms can be
detected in affected joints, bacterial RNA from many other
bacteria is also present, as was previously noted in studies of
other forms of inflammatory arthropathy.
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protein and self-antigens such as CD11a. However, the
precise role of bacterial antigens in pathogenesis has not
been defined, and it is unclear whether bacterial antigens
reach the joint in sufficient quantities to account for the
major sustained inflammation that can characterize ReA.
Using a reverse transcription (RT)-PCR technique to
detect bacterial 16S rRNA, we recently demonstrated that
transcriptionally active bacteria are present in synovial
tissue from patients with rheumatoid arthritis (RA) and
other arthropathies [14]. These bacteria were mainly
derived from commensals that are normally present in the
skin and gut, and we concluded that bacteria engulfed by
macrophages can reach the joint when macrophages are
recruited to the synovial membrane, particularly when
recruitment is increased by joint inflammation. We have
now applied this general technique for the detection of
bacteria to SF samples from patients with ReA and other
forms of postinfectious arthritis. The data show that the
same commensal bacteria can also be detected in SF
from these patients, whereas specific disease associated
bacteria can also be demonstrated in some cases.
However, bacterial rRNA sequences from disease associ-
ated bacteria were detected relatively infrequently as com-
pared with those from other bacteria also detected in the
joint. These findings have implications for our understand-
ing of the pathogenesis of postinfectious arthritis.
Materials and method
Patients
SF samples were collected by routine aspiration, mainly
from patients attending the Department of Medicine,
Addenbrooke’s Hospital, Cambridge, UK. Diagnoses were
established by history, serology and culture, as appropri-
ate (Table 1).
Isolation of RNA from synovial fluid and reverse
transcriptase PCR amplification of bacterial rDNA
Total RNA was isolated from 200 µl untreated centrifuged
SF using lysis in the presence of 500 µl phenol pH 4.0
and 100 µl chloroform isoamyl alcohol in a Hybaid Ribo-
lyserTM (Hybaid, Teddington, Middlesex, UK) according to
the manufacturer’s instructions, and recovered by precipi-
tation with propan-2-ol, dried under appropriate sterile
conditions, and then dissolved in diethylene pyrocarbonate-
treated water containing 0.1 mmol/l EDTA. Before the RT
step, an aliquot of total RNA was subjected to DNase
treatment with 1 unit DNase I (Cambridge Bioscience,
Cambridge, UK), involving incubation at 37°C for 30 min
followed by denaturation of the enzyme by incubation at
75°C for 15 min, whereas the remaining aliquot was not
treated. This was to allow comparisons between DNase
treated and untreated RNA.
Control bacterial rRNAs and total SF RNA were reverse
transcribed using the same method, as previously
described [14]. To eliminate the risk of contamination with
bacterial nucleic acids from external sources, all reagents
were prepared using distilled water irradiated with ultra-
violet at 254 nm for 2 min. Negative controls were
included at each stage of the RT-PCR procedure in order
to ensure that no contamination of samples occurred
during protocol implementation.
Bacterial ribosomal DNA fragments were amplified from
total cDNA and bacterial genomic DNA by PCR amplifica-
tion using universal, bacterial rRNA specific oligo-
nucleotide primers R1 and R2, as previously described in
detail [14]. All PCR negative samples were tested for
potential PCR inhibitors by the addition of 5 ng
Escherichia coli genomic DNA, to their cDNA, and
retested as described above. If PCR products of the
expected size (approximately 400 bp) were detected, then
these products were cloned into the PCR product cloning
vector pT7-blue (Novagen, Madison, Wisconsin, USA),
according to the manufacturer’s instructions, for sequenc-
ing and analysis as previously described [14].
Development of specific PCR tests
Having designed specific oligonucleotides that were
unique for a given bacteria sequence, these were tested
against a panel of 2 µl aliquots from 96 sequenced bacte-
ria PCR products inserted into recombinant E. coli.
Using standard reaction mixes and standard cycling times
(see above), different primers were tested at annealing
temperatures of 55, 60, 63 and 65°C. PCR products were
then visualized using gel electrophoresis. When the only
PCR product detected was from the positive control DNA
and the other 95 wells remained negative, a set of primers
was considered to be specific. If, however, the positive
control also failed before specificity was reached, then the
MgCl2 concentration was raised by 0.5 mmol/l increments
at the first temperature at which the positive control was
seen to fail. If this failed to get the positive control to work
before loss of specificity was reached, then the primers
were redesigned and the process repeated.
Results
SF samples were collected from 12 patients with various
forms of postinfectious arthropathy; 10 had clinical fea-
tures of ReA and two had postmeningococcal or post-
streptococcal arthritis. An additional two patients were
studied with undifferentiated spondyloarthropathy in which
a diagnosis of chronic ReA was considered possible.
Patient details are given in Table 1, along with the basis on
which the diagnosis was made. Total RNA was extracted
from the SF samples and approximately half was then
treated with DNase I, and then aliquots of both were sub-
jected to RT-PCR using universal primers R1 and R2 for
detection of bacterial 16S rRNA sequences. Of DNase
treated samples 11 out of 14 tested positive, asR3
compared with 12 out of 14 of the untreated samples. SF
from patient C was the only sample that tested positive
without DNase treatment and negative following DNase
treatment, indicating that bacterial 16S DNA was most
likely being detected rather than RNA. Although samples
from patients M and N were negative with and without
DNase treatment, all other samples had evidence of bac-
terial 16S rRNA, indicating the presence of ‘live’ transcrib-
ing bacteria in the inflamed joint.
Sequencing of the PCR products was then performed.
Twenty clones were picked from each PCR product and
sequenced. Only good quality, full-length (350–400 bp)
sequences were analyzed in detail; short sequences (less
than 200 bp) were ignored because the species from
which they came could not be accurately identified. A
summary of the total number of sequences analyzed from
each patient is detailed in Table 2. (Note that the primers
R1 and R2 fail to amplify Chlamydia 16S rRNA, and so
Available online http://arthritis-research.com/content/5/1/R1
Table 1
Clinical features of patients included in the study
Reverse transcription PCR using
Universal primers Specific primers
Patient Bacteria implicated DNase Non-DNase Yer Chlam E. coli Camp Clinical details
A Yersinia 6/20 2/20 + + Acute ReA (see [10]); positiveve serology 
(agglutination 1:2500) and T cell responses
B Enteric  10/20 7/20 + Acute ReA following gastroenteritis; organism 
unknown
C Meningococci Negative 2/20 + Acute postinfective arthritis; sore throat, rash, 
positive serology; daughter had meningococcal 
purpura and arthritis
D Streptococcus 17/20 5/20 + Chronic erosive seronegative oligoarthritis; 
persistent positive serology – very high ASOT 
(>1200 U) and anti-Dnase
E Chlamydia 5/20 5/20 + + Acute sexually acquired ReA; high T-cell mediated 
responses to CT
F Yersinia (?) 7/20 6/20 + Acute (?) ReA; positive serology, B27+ and T-cell 
responses; no enteritis
G Unknown 12/20 1/20 + Chronic seronegative oligoarthritis; culture positive 
Campylobacter infection 2 years pre-arthritis
H Unknown 11/20 5/20 + Chronic seronegative oligoarthritis
I Yersinia 8/20 9/20 + Acute ReA following gastroenteriitis; positive 
serology (IgM 1:640, IgG 1:2560, IgA <1:80) and 
T-cell responses
J Chlamydia 7/20 3/20 + Acute sexually acquired ReA; high T-cell mediated 
responses to CT
K Campylobacter 19/20 20/20 + Psoriatic arthritis complicated by culture positive 
enteritis and flare in joint symptoms (?ReA)
L Campylobacter 19/20 16/20 + Acute ReA following enteric infection
M Campylobacter Negative Negative Acute seronegative oligoarthritis and vasculitis; 
positiveve serology (IgM <1:80, IgG 1:640, IgA 
1:160)
N Campylobacter Negative Negative Sero-negative oligoarthritis; positive serology (IgM 
1:640, IgG 1:640, IgA 1:160) and T-cell 
responses
Universal (DNase and non-DNase) indicates the number of clones sequenced giving good quality sequence from PCR products obtained using
universal primers R1 and R2 from each patient, with and without DNase treatment. Specific indicates results of subsequent Yersinia (Yer),
Chlamydia (Chlam), Escherichia coli, and Campylobacter (Camp) specific PCR performed on the products obtained using universal primers.
ASOT, antistreptolysin O titre; CT, Chlamydia trachomatis.Arthritis Research and Therapy    Vol 5 No 1 Cox et al.
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Table 2
Bacterial sequences identified in synovial fluid from reactive arthritis and postinfectious arthritis patients
Bacteria (Non-DNase) Bacteria (DNase) Bacteria (Non-DNase) Bacteria (DNase)
Patient A
1 × E. coli (2) 2 × E. coli (5)
1 × Abiotrophia adiceins 1 × Pseudomonas (1)
1 × Pseudomonas (4)
1 × Streptococcus (9)
1 × Anabaena (1)
Patient B
2 × Propionibacterium acnes (1) 3 × Anabaena (1)
1 × Streptococcus (7) 1 × Mycobacterium (1)
1 ×  Anabaena (1) 1 × Staphylococcus (1)
1 × Lactobacillus (2) 1 × Peptostreptococcus (3)
1 × Actinomycetes sp. 1 × Bacillus (3)
1 × Unidentified Eubacterium 1 × Neisseria (1)
1 × Desulfovibrio sp.
1 × Brevundimonas sp.
Patient C
1 × P. acnes (1)
1 × Streptococcus (2)
Patient D
1 × Staphylococcus (1) 2 × P. acnes (1)
1 × Pseudomonas (6) 1 × Staphylococcus (2)
1 × Corynebacterium (3) 1  × Staphylococcus (3)
1 × Gamella (2) 1 × Corynebacterium (2)
CC29 Agrobacterium 1 × Nevskia ramosa (1)
1 × Anabaena (1)
1 × Lactobacillus (2)
1 × Methylobacterium (2)
1 × Streptococcus (2)
1 × Rhodococcus (2)
1 × Timone (2)
1 × Unidentified 
1 × Tetracoccus
1 × Comamonas
1 × Frankia
1 × Actinomycetes
Patient E
3 × Staphylococcus (1) 1 × Anabaena (1)
1 × Staphylococcus (3) 1 × Streptococcus (1)
1 × Streptococcus (8) 1 × Pseudomonas (1)
1 × Neviskia ramosa (1)
1 × Unidentified
Patient F
1 × Propionibacterium (2) 2 × Pseudomonas (2)
1 × Streptococcus (3) 1 × Propionibacterium (2)
1 × Anabaena (1) 1 × Anabaena (1)
1 × Stenotrophomonas 1 × Corynebacterium (1)
1 × Burkholderia 1 × Streptococcus (4)
1 × Actinomyces 1 × Afipia
Patient G
1 × Pseudomonas (5) 3 × P. acnes (1)
3 × Pseudomonas (5)
1 × Streptococcus (2)
1 × Streptococcus (5)
1 × Gamella (3)
1 × Neisseria (3)
1 × Lactobacillus (3)
1 × Peptostreptococcus (2)
Patient H
3 × Deinococcus (1) 3 × Staphylococcus (1)
2 × Neisseria (1) 2 × Lactobacillus (1)
1 × Bradyrhizobium (1)
1 × Bacillus (5)
1 × Peptostreptococcus (4)
1 × Anabaena (1)
1 × Taxeobacter
1 × Acinetobacter
Patient I
2 × Prevotella (2) 1 × Curtobacterium (1)
1 × Bacillus (4) 1 × Curtobacterium (2)
1 × Methylobacterium (1) 1 × P. acnes (1)
1 × Neisseria (1) 1 ×  Bradyrhizobium (1)
1 × P. acnes (1) 1 × Mycobacterium (2)
1 × Bradyrhizobium (1) 1 ×  Anabaena (1)
1 × Pseudomonas (2) 1 ×  Pseudomonas (2)
1 × Dunganella 1 × Unidentified Eubacterium
Patient J
1 × Corynebaterium (1) 1 × Corynebacterium (4)
1 × Staphylococcus (3) 1 × Staphylococcus (2)
1 × Paracoccus sp. 1 × Pseudomonas (1)
1 × Streptococcus (1)
1 × P. acnes (1)
1 × Bradyrhizobium (1)
1 × Nevskia ramosa (1)
Patient K
3 × Unidentified Eubacterium (1) 3 × Anabaena (2)
3 × Anabaena (2) 1 × Anabaena (3)
2 × P. acnes (1) 3 × P. acnes (1)
2 × Alacaligenes (1) 2 × Lactobacillus (2)
2 × Rhodococcus (1) 2 × Nocardioides (1)
1 × Streptococcus (6) 1 × Neisseria (2)
1 × Neisseria (2) 1 × Timone (1)
1 × Staphylococcus (1) 1 × Prevotella (1)
1 × β-Proteobacterium 1 × Unidentified Eubacterium (1)
1 × Unidentified Eubacterium 1 × Staphylococcus (1)
1 × Brevibacterium  1 × Burkholderia
1 × Burkholderia 1 × Kineosporia
1 × Nitrosomonas 1 × Spirochaeta
Patient L
4 × Unidentified Eubacterium (1) 9 × Unidentified Eubacterium (1)
3 × Gamella (1) 3 × Micrococcus (1)
1 × Staphylococcus (1) 1 × Micrococcus (2)
1 × P. acnes (1) 1 × Methylobacterium (1)
1 × Pseudomonas (3) 1 × Methylobacterium (2)
1 × Corynebaterium (1) 1 × Alcaligenes (2)
1 × Timone (1) 1 × Staphylococcus (1)
1 × Rhodococcus (1) 1 × Afipia
1 × Peptostreptococcus (1) 1 × Pinus strobus
1 × Neisseria (2)
1 × Methylobacterium (1)
Details of the bacterial species identified by sequencing clones obtained following reverse transcription PCR. Twenty clones were picked from
each PCR product. Only good quality, full-length sequences (350–400 bp) were analyzed in detail; shorter sequences were ignored because the
species from which they came could not be accurately identified. Each column shows the identity and the number of sequences obtained. The
numbers in brackets after species names serve to identify different sequences from the same organism. Full details of the sequences can be
obtained from the authors on request.Chlamydia sequences would not be expected to be found
in this analysis; their presence is investigated below when
Chlamydia-specific primers were developed and used.)
As previously noted in the study of bacterial rRNA
sequences amplified from synovium of RA patients [14],
each patient’s SF contained a diverse range of bacteria
with no one species dominating the population detected.
Interestingly, with the possible exception of patient D, in
whom Streptococcus spp. were detected, no evidence of
the bacteria thought to be the causative agent for arthritis
was detected in any of the samples. Although there was a
reasonable correlation between the bacteria detected with
and without DNase treatment (e.g. patient K), some
samples showed the presence of quite different bacteria
in the DNase treated and untreated samples (e.g. patient
H). This probably reflects the relatively small number of
sequences generated from each sample. In our previous
study in which 46 sequences from each tissue sample
were analysed [14], there was only approximately 80%
correlation between the bacteria detected when the same
PCR product was cloned and sequenced on separate
occasions. This indicates that even with a large amount of
sequencing only a relatively small proportion of the total
bacteria present within the joint are detected.
Detection of specific disease associated bacteria
Having failed to detect evidence of bacterial 16S rRNA
from any of the causative agents in any of the SF samples
tested, primers were designed that were specific for
Yersinia spp., Campylobacter spp. and Chlamydia spp.;
as a control, primers to detect E. coli sequences were
also used because E. coli rRNA had been detected in SF
samples in this and previous studies (Table 2). As a rapid
means of testing the specificity of these oligonucleotides,
a 96-well plate was set up in which each well contained
200 µl recombinant E. coli with an inserted cloning vector
containing the 16S rRNA sequence of one of the bacteria
detected during the study. This allowed a diverse range of
different bacteria to be screened using various specific
oligonucleotides. In addition, because the 16S rRNA
sequences expressed in E. coli were from bacterial prod-
ucts actually isolated from synovial tissue and SF, they
were a valid test of the ability of the oligonucleotides to
distinguish between different bacteria likely to be present
in the joint.
Using this technique we were able to generate oligo-
nucleotides (Table 3) that could specifically detect
Yersinia spp., Campylobacter spp., Chlamydia trachomatis
and E. coli sequences. When these primers were tested in
the 14 patients described in Table 1, positive results were
obtained in only two cases. In patient A with Yersinia-
induced ReA a product was obtained using Yersinia-
specific primers, whereas for patient E with
Chlamydia-induced ReA a product was obtained with
Chlamydia-specific primers. Subsequent cloning and
sequencing of the specific PCR products generated indi-
cated that the Yersinia sp. detected was either Yersinia
pseudotuberculosis or  Y. pestis (very closely related).
Serology indicated that this patient had indeed been
infected with Yersinia pseudotuberculosis [10]. Likewise,
the products obtained with Chlamydia-specific primers
were from C. trachomatis.
Use of Campylobacter-specific primers also produced
products in patients K and L, both of whom were thought
to have Campylobacter-triggered ReA. However, subse-
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Table 3
Primers and amplification conditions used in the study
Annealing MgCl2  Size of 
temperature concentration product 
Forward primer (5′–3′) Reverse primer (5′–3′) Specific for /time (mmol/l) (bp)
AGTAGTTTACTACTTTGCCG  ACTGCTGCCTCCCGTAGGAG  Universal (R1 and R2) 58°C/60 secs 1.5 350
CATAACGTCGCAAGACCAAA GTGCAATATTCCCCACTGCT E. coli 58°C/45 secs 1.5 187
TTGGGAATAACGGTTGGAAA TGTCTCAGTCCCAGTGTTGG Chlamydia spp. 59°C/30 secs 1.5 203
CGCACGGGTGAGTAAGGTA GCGTCATAGCCTTGGTAAGC Campylobacter spp. 66°C/1 min 2.5 170
AGTAGTTTACTACTTTGCCG CCGATGGCGTGAGGCCCTAA Yersinia spp. 65°C/30 secs 3.5 154
CGCACGGGTGAGTAAGGTA GCTTAACACAAGTTGACTAG Campylobacter jejuni 63°C/30 secs 2.5 70
CGCACGGGTGAGTAAGGTA GTCTTACATAAGTTAGATA Campylobacter concisus  55°C/30 secs 2.0 70
CGCACGGGTGAGTAAGGTA ATACCTCATACTCCTATTTAAC Bacteroides ureolyticus 55°C/30 secs 2.0 70
Specific oligonucelotides were designed as described here. Standard reaction mix was used with each set of oligonucleotides (see Materials and
method), although annealing conditions varied, as did MgCl2 concentration. Denaturation conditions were always 94°C for 1 min and extension
was performed at 72°C for 1 min (10 min final extension). Typically 35–40 cycles were performed. If no PCR product was detected, then a second
round of amplification was performed using 2 µl of PCR product as template.quent sequencing of the Campylobacter-specific products
did not reveal the presence of Campylobacter jejuni or
Campylobacter coli, the bacteria most commonly associa-
ted with ReA. SF from patient K was found to contain a
Campylobacter concisus sequence, whereas that from
patient L contained a different Campylobacter concisus
sequence and a Bacteroides ureolyticus sequence (a
species with rRNA very closely related to that of Campylo-
bacter spp.). Neither of these gut and urogenital tract
bacteria has previously been reported to be associated
with ReA.
Further investigations of Campylobacter sequences
detected
The detection of Campylobacter-related sequences,
which appeared to be specific for samples taken from
patients with Campylobacter-associated ReA, raised the
possibility that we had identified new Campylobacter spp.
that might be associated with disease. To address this
issue further, efforts were made to gather more sequence
data on the Campylobacter spp. identified. The Campylo-
bacter-specific oligonucleotides only generate a 150 bp
fragment for sequence, whereas identification of the PCR
product generated using universal primers R1 and R2 that
contained the Campylobacter sequences should reveal
400 bp of sequence from that bacterium. However, in
spite of isolating more than 1000 individual clones from
each of the PCR products obtained using ‘universal’
primers, and screening using Campylobacter-specific
primers, we were unable to identify a single clone that
contained the Campylobacter sequence (but note that
amplification of the ‘universal’ PCR product using the
Campylobacter-specific primers confirmed that the
Campylobacter sequence was present within the popula-
tion). This would appear to indicate that the Campylo-
bacter spp. detected by specific PCR within the product
obtained using ‘universal’ PCR represent less than 0.1%
of the total bacteria found within the inflamed joints of
these patients. However, the copy number of 16S rRNA
per cell can vary enormously from bacteria to bacteria, and
this low frequency of Campylobacter sequences could
reflect less transcriptionally active bacteria being
swamped by more active bacteria.
Specific oligonucleotides were then designed to distin-
guish between Campylobacter concisus,  Campylobacter
jejuni and B. ureolyticus. Although these species are very
closely related, oligonucleotides were developed that could
differentiate between the three (Table 3). Large scale
screening of ‘universal’ 16S rRNA PCR products gener-
ated from SF and synovial tissue from RA, non-RA and ReA
patients (48 samples tested in total) revealed that Campylo-
bacter concisus and B. ureolyticus could be detected in
five samples (two Campylobacter-associated ReA, one
Chlamydia-associated ReA, one RA sample and one undif-
ferentiated arthritis sample). In contrast, Chlamydia tracho-
matis sequences were only ever detected in samples taken
from patients with Chlamydia trachomatis associated ReA
(four out of six samples from patient E, obtained at different
time points over 3 years of active arthritis, and additional
patients subsequent to this study), whereas 41 non-
Chlamydia associated samples were negative. In addition
Y. pseudotuberculosis sequences were only detected in
samples from patients with Y. pseudotuberculosis associ-
ated ReA (one out of three samples tested), whereas all
controls were negative. This would imply that the Campylo-
bacter sequences we detected in ReA SF were the result
of very low levels of commensal Campylobacter spp.,
rather than specific disease causing bacteria. Campylo-
bacter jejuni sequences were not detected in any samples,
implying that live Campylobacter jejuni does not reach the
inflamed joint.
Discussion
Although bacterial antigens, DNA and RNA from the arthritis-
triggering organism have previously been reported in SF
and tissue from ReA patients, the presence of a wide
variety of bacterial species was unexpected, but we
reported very similar findings in our previous study of RA
and other forms of chronic arthritis [14]. The source of
these organisms is not known but may be environmental
or from the indigenous microflora. As noted, we took strin-
gent precautions to avoid laboratory contamination, and
the organisms identified cannot all be accounted for by
skin bacteria introduced into the SF at the time of percuta-
neous aspiration. We did not surgically remove the skin at
the aspiration site to avoid contamination with skin flora,
but our results are rather similar to those obtained by
others who took this precaution [15]. As tests of the effec-
tiveness of our precautions, reagent controls were always
negative, and when normal synovium was tested (in a pre-
vious study) no bacterial rRNA was obtained. In the
present study two SF samples were also negative when
DNase was used. In addition, the sequences obtained
varied between patients (including the E. coli sequences),
arguing against laboratory contamination. Together, this
constitutes strong evidence of the ability of commensal
organisms such as E. coli to colonize inflamed joints; the
gut in different patients would be expected to contain a
range of E. coli ‘subspecies’, with minor variant rRNA
sequences.
Our results are similar to those detailed in other recently
published reports [16–18], although our use of RT-PCR
rather than PCR is likely to be responsible for the high pro-
portion of SF samples in which we could detect bacteria.
Nevertheless, all of the studies have emphasized that bac-
terial nucleic acids can be detected in many forms of
inflammatory arthropathy (RA, inflammatory osteoarthritis,
crystal arthropathy [18]) in addition to ReA, and that
organisms associated with ReA can be found in syn-
ovium/SF of patients with other diagnoses [16]. Many
Arthritis Research and Therapy    Vol 5 No 1 Cox et al.
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acnes and Streptococcus epidermidis) were seen in our
own previous study, implying that their presence in the
joint is not disease specific and that they are likely to be
opportunistic colonizers of inflamed joints. P. acnes has
also be implicated by some investigators in the pathogen-
esis of SAPHO (synovitis, acne, pustulosis, hyperostosis,
osteitis) [19]; our data confirm that the organism can
access joints, but if it plays a role in SAPHO then this
must reflect an abnormal response to the organism in that
disease because it is clearly present in synovium from
other conditions. Likewise, although streptococci were
identified in a patient with seronegative erosive arthritis
and persistent high titres of antistreptococcal antibodies,
the role of streptococci in this case must remain specula-
tive because streptococcal rRNA was amplified from six
other ReA and several RA patients in the previous study.
The present analysis of SF from ReA patients indicates
that, even in patients in whom an infectious agent is
known to be involved in the pathogenesis of the arthritis,
detection of that infectious agent by universal PCR can
be masked by the high level of commensal bacteria
present. Their presence suggests trafficking from sites
such as the gut (an idea strengthened by the detection
of E. coli sequence in all samples). In enteric ReA active
bowel inflammation will inevitably affect the barrier func-
tion of the gut wall, allowing systemic access by gut
flora. Nonsteroidal drugs have also been reported to
impair gut permeability and mucosal competence
[20,21], and most of our patients were taking such
drugs. The fact that sequences from species of bacteria
that definitely play a role in triggering arthritis are in a
distinct minority among all of the sequences detected
within ReA SF raises questions about the role of intra-
articular bacteria in the pathogenesis of ReA, and ques-
tions the practical use of universal PCR to diagnose
ReA. Although the technique shows increased sensitivity
over detection of 16S rDNA, this increased sensitivity
may also mask detection of the causative agent.
However, the use of specific primers showed complete
specificity (Yersinia and  Chlamydia rRNAs were only
detected in patients in whom other evidence pointed to
the involvement of these organisms) but low sensitivity in
the case of Yersinia, because only one out of three
patients with ReA thought to be related to Yersinia infec-
tion had evidence of the specific rRNA in SF.
The findings from investigations in patients with Campylo-
bacter-induced ReA were unexpected. Although Campylo-
bacter sequences were isolated, Campylobacter jejuni
was never detected in any of the samples tested. Our data
are unable to distinguish clearly between the possibility
that certain Campylobacter spp. other than Campylo-
bacter jejuni can sometimes be associated with ReA, and
the dissemination of commensal Campylobacter spp. to
inflamed joints along with other components of gut flora.
The latter is more likely in view of the isolation of Campylo-
bacter sequences from patients with diagnoses other that
ReA, but it is not inconceivable that a normal member of
the gut flora could, under the appropriate circumstances,
be involved in triggering ReA; ReA secondary to Clostrid-
ium difficile infection falls into this category [22].
In conclusion we have shown that, in forms of arthritis
associated with preceding infection, rRNA from the organ-
ism responsible can sometimes be demonstrated within
SF. However, rRNAs from the commensal flora of gut and
skin are even more easily detected. What are the implica-
tions of these findings for our understanding of the patho-
genesis of postinfectious arthritis? First, the fact that
rRNA sequences from disease associated organisms are
a minority of those detected in the joint does not neces-
sarily imply that the disease associated organisms have no
role in pathogenesis locally. They may synthesize antigens
that evoke vigorous T-cell mediated immune responses, as
suggested by the consistent finding of prominent
responses to triggering organisms in ReA SF T cells
[23,24]. In contrast, the immune system is usually tolerant
of gut flora [25]. It is clear that the traffic of organisms to
the joint does not lead to their replication and sepsis,
because the joints remain sterile when culture studies are
carried out. Presumably, they are controlled by innate
immune mechanisms, including macrophages and poly-
morphs; indeed, it is likely that many of the organisms
detected were engulfed by phagocytes in the periphery
that were then recruited to the inflamed joint. Neverthe-
less, although the organisms may be rapidly eliminated or
contained, and may not elicit specific immune responses,
they may have a proinflammatory effect because of the
effects of component such as lipopolysaccharide, bacter-
ial DNA and bacterial heat shock proteins on the innate
immune system [26–29]. These effects may amplify
inflammation initially triggered by an immune response to
an ReA-associated organism. The duration and severity of
arthritis following infection could reflect the efficiency with
which these generic proinflammatory mechanisms are
brought under control.
Conclusion
RT-PCR using universal primers reveals the presence of
bacterial 16S rRNA in SF from patients with ReA or
postinfectious arthritis. However, the majority of the
sequences detected are derived from commensal bacteria
that traffic, probably in macrophages, to the inflamed joint.
16S rRNA from organisms that are responsible for
causing arthritis can also be detected but only in a minor-
ity of cases, and only by using species-specific primers for
amplification. This might reflect low abundance of these
bacteria in SF, but truly quantitative studies targeting
organism chromosomal and DNA and using real-time PCR
would be required to confirm this idea.
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